● neutral
Impact
PhasePhase 1a/1b
Time to marketAB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
AB-101 Updated Nov 10
What to watch
The next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
Bull case
- The FDA clinical hold on AB-101's IND was lifted on October 22, 2026, a positive regulatory de-risking event that allows U.S. clinical development to resume.
- Phase 1a/1b data presented at AASLD 2025 showed AB-101 was well tolerated up to 30mg QD for 28 days in chronic HBV patients, with 83% mean maximal PD-L1 receptor occupancy at the 30mg dose, suggesting target engagement.
- AB-101 is an oral small-molecule PD-L1 inhibitor, a novel approach for chronic HBV that could restore T-cell function against infected liver cells, potentially as part of a functional cure combination.
Bear case
- AB-101 is still in Phase 1a/1b, an early stage with a high risk of failure in later trials; many drug candidates fail to show efficacy in Phase 2.
- The clinical hold was only recently lifted (October 22, 2026), and the company is still evaluating next steps, meaning there is no clear timeline for advancing the program.
- Arbutus has no approved products and remains a clinical-stage biotech; the stock trades near its 52-week low of $3.50, reflecting ongoing execution risk.